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A B S T R A C T
The national Croatian improved diagnostic and therapeutic guidelines for prema-
lignant lesions of the uterine cervix are presented: for atypical squamous cells of unde-
termined significance (ASCUS), for cervical intraepithelial neoplasia (CIN I, CIN II,
CIN III) and for microcarcinoma (FIGO grade Ia1). Separately are presented the guide-
lines for abnormal glandular epithelium: atypical glandular cells of undetermined sig-
nificance (AGCUS) and cervical glandular intraepithelial neoplasia (CGIN). The gui-
delines are created according to the guidelines of the FIGO. Improved diagnostic and
therapeutic guidelines was presented and accepted at the Symposium of the Croatian
Society for Colposcopy and Cervical Pathology and of the Croatian Society of Gynecolo-
gists and Obstetricians of the Croatian Medical Association, held on November, 25th
2000. There are presented the chief differences and the some cost-benefit aspects between
the guideline s before and the new one.
On the occasion of the 30th anniver-
sary of the »Croatian Anti-Cancer Lea-
gue« three years ago, we showed the then
new »Diagnostic and therapeutic protocol
for early detection of changes in the squa-
mous epithelium of the cervix«1. Since
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then we have acquired new knowledge on
the effects of infection with human papi-
llomavirus (HPV), and we have at our
disposal modern diagnostic and therape-
utic methods. We have therefore percei-
ved the need to revise our procedure both
diagnostically and therapeutically. Toget-
her with the cervical intraepithelial neo-
plasia (CIN), we have dealt with atypical
osquamous cells of undetermined signifi-
cance (ASCUS), and atypical glandular
cells undetermined significance (AGCUS).
On November 25, 2000, a symposium
was held in Zagreb on »Problems and di-
lemmas in the diagnostics and treatment
of suspected changes in the cervix«, whe-
re we showed the detailed Protocol, sepa-
rately for each entity, and which was
adopted as such. In developing our own
»Improved diagnostic and therapeutic
guidelines for premalignant lesions of the
uterine cervix«, we took into consider-
ation the recommended directives by the
International Federation of Gynecology
and Obstetrics (FIGO)2.
Compared to our 1998 Protocol, we lay
greater stress on the target anti-inflam-
matory therapy, accompanying atypias of
the cervix, and we treat it immediately,
before any other diagnostic procedure.
Regarding the availability of HPV
DNK examination (which is on the Reim-
bursement list of the Croatian Health In-
surance Institute), PCR and HPV DNA
Hybrid Capture II methods are done as a
routine. In our Improved Guidelines, HPV
DNA typing is proposed immediately fol-
lowing the cytological analysis. Further
procedures and recommended check up
intervals depend on the findings of HPV
isolation with high or low oncogenic risk3.
The Improved Guidelines develop the
procedures for cytological diagnoses of
ASCUS and AGCUS. We consider it nec-
essary give recommendations for every-
day practice, since they can constitute as
much as 4% of all PAPA tests, while all
the other abnormalities account for 1.7%.
In 15–50% ASCUS (probably in about
20%) this is really high-grade squamous
intraepithelial lesion (HSIL)4,5. We there-
fore recommend cytological check in 3 to
6 months, and if the abnormal finding
persists, the procedure is identical to that
for evident SIL6–8. In 50% AGCUS, this is
really a high-grade squamous or glandu-
lar lesion, and FIGO and we were more
active in searching for histopathological
confirmation or exclusion of glandular
atypia2,4.
We would particularly like to stress
the significance of unsatisfactory colpo-
scopy, when the squamocolumnar junc-
tion or lesion is not, or is just partly, visi-
ble. In this case it is necessary to perform
the endocervical curettage, and, if the le-
sion is only partly visible, then directed
biopsy should also be performed.
The colposcopic assessment of the va-
gina is also very important because it can
contain changes linked to HPV infection
in the form of condylomatous lesions, as
well as vaginal intraepithelial neoplasias
(VAIN).
In CIN III (cytological), the diagnostic
procedure is maximally shortened to con-
firm or exclude the diagnosis histopatho-
logically as soon as possible9. We consider
that in case of developed CIN III, previ-
ous HPV DNK typing makes no differ-
ences in the further treatment (Figure 1).
As opposed to the previous Protocol
and FIGO, we recommend that, following
the directed biopsy, cytological and col-
poscopical check up should be introduced,
regardless of the age or reproduction sta-
tus of the patient (time interval depend-
ing on the confirmed changes and HPV
DNK typing result). We have decided to
take this step by the relatively high num-
ber of regression of findings, especially in
the case of mild or unilocular minor chan-
ges (up to 22.5% regression with histo-
pathologically confirmed HCIN on a
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directed biopsy specimen to CIN I, koil-
ocytosis or only cervicitis on the cone)10,11.
In this way we can considerably decrease
the number of unnecessary operations
(over-treatment), but the patient should
continue with follow-up. This recommen-
dation does not apply to the cases of his-
topathological suspicion of microinvasive
carcinoma (MIC) and stronger lesions.
Our Improved Guidelines include a
more active approach to the treatment of
persisting CIN I and CIN II, where the
recommended time for an appropriate
treatment, in the case of HPV type of
high oncogenic risk + CIN I and CIN II
(regardless of the HPV type) is one year.
We are extremely patient in the case of
CIN I + HPV type of low oncogenic risk
where the time period is extended to 2
years, leaving scope for spontaneous re-
gression or continuation of pregnancy12,13.
In persisting CIN II and CIN III, as
well as the progression in MIC, a diag-
nostic-therapeutic operation by one of the
excision methods must be done without
delay, depending on the age, parity and
colposcopic finding9,12. In FIGO Stage Ia1
(depth of invasion less than 3 mm and
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ASCUS = atypical squamous cells of undetermined significance; CIN = cervical intraepithelial
neoplasia; HPV = human papillomavirus; neg. HPV DNA typing negative; Low risk = HPV DNA of
low oncogenic risk; High risk = HPV DNA of high oncogenic risk; * when unsatisfactory colposcopy
and unvisible lesion in any case to perform endocervical curettage
Fig. 1. Diagnostic guidelines at abnormal cytologic findings indicating pre-invasive
lesions of squamous epithelium of the uterine cervix.
free lymphatic-vascular space), the most
frequent treatment is diagnostical-thera-
peutical cold-knife conization14 (Figure 2).
In recent years, there is increased evi-
dence of relative and absolute incidence
of cervix adenocarcinoma. It appears that
the cervical glandular intraepithelial
neoplasia (CGIN) together with SIL,
presents a range of changes from mild to
grave form15. In the cytological Bethesda
system there is differential diagnosis of
AGCUS5. A stronger finding is glandular
intraepithelial lesion Grade I and Grade
II (GIL I-II) and GIL III, corresponding to
adenocarcinoma in situ (AIS)15. Histolo-
gically speaking, this is low and high-
-grade CGIN.
AGCUS incidence in the screened pop-
ulation is 0.2–0.6%. In about 50% AGCUS
these are really serious glandular and/or
squamous intraepithelial lesions, namely
with 40% AIS there is High SIL4. If the
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HPV-LR = HPV of low oncogenic risk; HPV-HR = HPV of high oncogenic risk; * = when previous PAPA
test was CIN III;
o
= LETZ or one of local ablative methods; * = guideline for CIN I; ** = guideline for
CIN II; *** = guideline for CIN III; “ LETZ or one of excision methods
Fig. 2. Therapeutic guidelines in histopathologically confirmed pre-invasive lesions of
the squamous epithelium of uterine cervix.
initial PAPA test indicates GIL I and GIL
II, a colposcopic assessment and histo-
pathological confirmation are required
immediately, and in case of suspected AIS
or an evident AIS diagnosis, the same
will be done. If the lesion is also col-
poscopically visible, directed biopsy should
be performed. Endocervical curettage
should be done in any case, and in women
over 35, fractional curettage should also
be done16. When the PAPA test indicates
AGCUS of endometrial cells, fractional
curettage or hysteroscopy with endome-
trial biopsy are indicated2 (Figure 3).
When histopathology (followed by
AGCUS and AIS-cytology) shows a nor-
mal finding or GIL I, cytological check up
(with Cytobrush cell collector) is recom-
mended after two months. The persis-
tence of AGCUS, GIL I, GIL II and AIS on
control findings indicates diagnostic-the-
rapeutic surgery – cold-knife conization.
In the case of GIL II and AIS (histo-
pathologically), the diagnostic – thera-
peutic surgery is required immediately4.
It is suggested that the cone have a cylin-
drical shape to include all glandular
crypts14,15 (Figure 4).
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AGCUS = atypical glandulae cells of undetermined significance; AIS = adenocarcinoma in situ; GIL = glandular
intraepithelial lesion;
#
= colposcopy with use of endocervical speculum; * = fractional curettage in women
over 35 years or with abnormal endometrial cells; HSC- hysteroscopy
Fig. 3. Diagnostic guidelines at abnormal cytological findings indicating pre-invasive
lesions of glandular epithelium of the uterine cervix.
About half of the verified AIS were in
combination with a co-existing CIN. The-
re is therefore a real danger of the over-
look the glandular lesion and diagnosing
and treating just the squamous compo-
nent, which can be very serious, espe-
cially when applying some of the ablative
treatment15.
It is hard to speak about the cost-effec-
tiveness of the Protocol because there are
dual prices on the health market for iden-
tical health services (those reimbursed by
the Croatian Institute for Health Insur-
ance, and those charged in private health
institutions). Regarding the unrealistic
low prices (according to the »Blue book«)
of cytology and colposcopy (PAP test KN
12.00, colposcopy KN 21.10; (1 US$ = 8.3
KN), they are even multiply far more
cost-effective than presently really costly
HPV DNK typing (Hybride Capture II
HPV DNA, about KN 250.00, and PCR
HPV DNA about KN 800.00). Lately
there is a possibility of HPV DNK typing
reimbursed by the Health Insurance In-
stitute, but it was contracted with one
laboratory in Zagreb only, which does not
correspond to real needs. This is why
HPV DNK typing is hardly acceptable fi-
nancially, although it is a valuable addi-
tional datum for clinicians in planning
the strategy of treatment or monitoring
the patients about the changes connected
with HPV infection.
An additional cytological and colpo-
scopic control following the biopsy is fi-
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HPD = histopathologic diagnosis; ECC. = endocervical curettage; GIL = glandular intraepithelial lesion; AGCUS =
atypical glandular cells of undetermined significance; AIS = adenocarcinoma in situ; * = pick up endocervical smear with
Cytobrush cell collector;
#
= cold knife conization
Fig. 4. Therapeutic guidelines in histopathologically confirmed pre-invasive lesions of
the glandular epithelium of uterine cervix.
nancially acceptable because about 20%
unnecessary surgeries can be avoided.
Since there are insufficient data on the
annual number of conizations in Croatia,
we have made a calculation based on 100
patients 20% fewer conizations, trans-
formed into the price of hospitalization,
the operation and the histopathological
processing of the cone, present a saving of
KN 48,707.00. This saving only includes
the hospitalization and the operation,
and does not include a 30-day sick leave
or later complication in possible preg-
nancy. The rate of post-operative cytologi-
cal and colposcopic checks is the same
even if the operation is not performed, so
these checks do not incur greater costs. If
progression in the finding is detected dur-
ing the follow-up, surgical treatment can
still be performed, but normal pregnancy
is still possible in the meantime.
Smaller and more sparing procedures
done in the outpatients’ clinic would be
far more cost-effective, but they are not
reimbursed according to the »Blue book«,
and are done for outpatients in private
clinics only.
Although every patient with prema-
lignant changes on the cervix needs an
individual approach in the treatment,
due to age, reproductive, socio-economic
and psychical status, some general guide-
lines are common to all. We therefore
think it justified to have diagnostic-ther-
apeutical Protocols, which will provide
basic guidelines for the treatment of such
patients, allowing for corrections due to
each individual case. We think that act-
ing in accordance with the Improved Pro-
tocol will reduce both the under-treat-
ment and the over-treatment. We will be
able to speak about its cost-effectiveness
only after the Protocol has been applied
in the practice for some time.
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POBOLJ[ANI HRVATSKI NACIONALNI DIJAGNOSTI^KO TERAPIJSKI
POSTUPNIK ZA PREMALIGNE PROMJENE VRATA MATERNICE S
NEKIM »COST-BENEFIT« ASPEKTIMA
S A @ E T A K
U Hrvatskom nacionalnom revidiranom dijagnosti~ko terapijskom postupniku za
premaligne promjene vrata maternice prikazani su postupnici za atipi~ne plo~aste sta-
nice neodre|enog zna~enja (ASCUS), cervikalnu intraepitelnu neoplaziju (CIN I, CIN
II, CIN III) te mikroinvazivni karcinom (FIGO stadij Ia1). Odvojeno su dani postupnici
za atipi~ne `ljezdane stanice neodre|enog zna~enja (AGCUS) i cervikalnu glandularnu
intraepitelnu neoplaziju (CGIN). Postupnici su na~injeni u skladu s najnovijim FIGO
preporukama. Revidirani dijagnosti~ko terapijski postupnik je prikazan i usvojen na
simpoziju Hrvatskog dru{tva za kolposkopiju i bolesti vrata maternice i Hrvatskog
dru{tva ginekologa i opstetri~ara HLZ-a odr`anom 25. studenog 2000. godine. Prika-
zane su glavne razlike u odnosu na pro{li postupnik i neki aspekti njegove isplativosti.
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